On the Record · Regeneron Pharmaceuticals

Regeneron Pharmaceuticals acquisitions, on the record

The businesses Regeneron Pharmaceuticals bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Decibel Therapeutics, Inc. Word for word“In August 2023, we entered into an Agreement and Plan of Merger to acquire Decibel, and in September 2023, we completed the acquisition of Decibel.” 10-K for 2023	acquisition	In August 2023, we entered into an Agreement and Plan of Merger to acquire Decibel, and in September 2023, we completed the acquisition of Decibel.	—
Checkmate Pharmaceuticals, Inc. Word for word“In 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc. for a total equity value of approximately $ 250 million.” 10-K for 2023	acquisition	—	approximately $ 250 million
Libtayo worldwide rights (from Sanofi) Word for word“Payments for the Libtayo intangible asset of $207.8 million and $1.027 billion in 2023 and 2022, respectively, were related to our acquisition (including contingent consideration paid) of the exclusive right to develop, commercialize, and manufacture Libtayo worldwide (as described in Part I, Item 1. "Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology " above).” 10-K for 2023	acquisition	—	Payments for the Libtayo intangible asset of $207.8 million and $1.027 billion in 2023 and 2022
2seventy bio, Inc.'s oncology and autoimmune preclinical and clinical stage cell therapy pipeline Word for word“In April 2024, we acquired full development and commercialization rights to 2seventy bio's oncology and autoimmune preclinical and clinical stage cell therapy pipeline.” 10-K for 2024	acquisition	April 2024	—
Exclusive worldwide rights to Libtayo (from Sanofi) Word for word“Payments for the Libtayo intangible asset of $125.7 million, $207.8 million, and $1.027 billion in 2024, 2023, and 2022, respectively, related to our acquisition (including contingent consideration paid) of the exclusive right to develop, commercialize, and manufacture Libtayo worldwide.” 10-K for 2024	agreed acquisition	2022	$1.027 billion

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2021-12-31	$0
2022-12-31	$230.3 million
2023-12-31	$54.9 million
2024-12-31	$16.5 million
2025-12-31	$3.3 million

Deal filings since 2016

2026-10-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-03-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-12-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-06-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-09-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-01-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-08-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-08-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-07-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-05-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-04-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-05-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-04-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-01-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-12-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-01-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-03-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-02-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-12-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-11-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-09-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-03-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-02-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Regeneron Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-04. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.